Skip to main navigation Skip to search Skip to main content

Effect of nateglinide on the incidence of diabetes and cardiovascular events

Rury R Holman, Steven M Haffner, John J McMurray, M Angelyn Bethel, Björn Holzhauer, Tsushung A Hua, Yuri Belenkov, Mitradev Boolell, John B Buse, Brendan M Buckley, Antonio R Chacra, Fu-Tien Chiang, Bernard Charbonnel, Chun-Chung Chow, Melanie J Davies, Prakash Deedwania, Peter Diem, Daniel Einhorn, Vivian Fonseca, Gregory R FulcherZbigniew Gaciong, Sonia Gaztambide, Thomas Giles, Edward Horton, Hasan Ilkova, Trond Jenssen, Steven E Kahn, Henry Krum, Markku Laakso, Lawrence A Leiter, Naomi S Levitt, Viacheslav Mareev, Felipe Martinez, Chantal Masson, Theodore Mazzone, Eduardo Meaney, Richard Nesto, Changyu Pan, Rudolf Prager, Sotirios A Raptis, Guy E H M Rutten, Herbert Sandstroem, Frank Schaper, Andre Scheen, Ole Schmitz, Isaac Sinay, Vladimir Soska, Steen Stender, Gyula Tamás, Gianni Tognoni, NAVIGATOR Study Group

    477 Citations (Scopus)

    Abstract

    The ability of short-acting insulin secretagogues to reduce the risk of diabetes or cardiovascular events in people with impaired glucose tolerance is unknown.
    Original languageEnglish
    JournalNew England Journal of Medicine
    Volume362
    Issue number16
    Pages (from-to)1463-76
    Number of pages14
    ISSN0028-4793
    DOIs
    Publication statusPublished - 22 Apr 2010

    Fingerprint

    Dive into the research topics of 'Effect of nateglinide on the incidence of diabetes and cardiovascular events'. Together they form a unique fingerprint.

    Cite this